1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Toxoplasmosis - Pipeline Review, H2 2014

Toxoplasmosis - Pipeline Review, H2 2014

  • October 2014
  • -
  • Global Markets Direct
  • -
  • 24 pages

Toxoplasmosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Toxoplasmosis - Pipeline Review, H2 2014’, provides an overview of the Toxoplasmosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Toxoplasmosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Toxoplasmosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Toxoplasmosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Toxoplasmosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Toxoplasmosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Toxoplasmosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Toxoplasmosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Toxoplasmosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Toxoplasmosis - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Toxoplasmosis Overview 5
Therapeutics Development 6
Pipeline Products for Toxoplasmosis - Overview 6
Pipeline Products for Toxoplasmosis - Comparative Analysis 7
Toxoplasmosis - Therapeutics under Development by Companies 8
Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes 9
Toxoplasmosis - Pipeline Products Glance 10
Early Stage Products 10
Toxoplasmosis - Products under Development by Companies 11
Toxoplasmosis - Products under Investigation by Universities/Institutes 12
Toxoplasmosis - Companies Involved in Therapeutics Development 13
Snowdon Inc. 13
Toxoplasmosis - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Molecule Type 15
Drug Profiles 17
SND-226 - Drug Profile 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
toxoplasmosis vaccine (SAG1) - Drug Profile 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
toxoplasmosis vaccine - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
SNT-18 - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody for Toxoplasmosis - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Toxoplasmosis - Dormant Projects 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

Number of Products under Development for Toxoplasmosis, H2 2014 6
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 9
Comparative Analysis by Early Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Products under Investigation by Universities/Institutes, H2 2014 12
Toxoplasmosis - Pipeline by Snowdon Inc., H2 2014 13
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Stage and Molecule Type, H2 2014 16
Toxoplasmosis - Dormant Projects, H2 2014 22

List of Figures

Number of Products under Development for Toxoplasmosis, H2 2014 6
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H2 2014 7
Number of Products under Investigation by Universities/Institutes, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 10
Assessment by Monotherapy Products, H2 2014 14
Number of Products by Top 10 Molecule Type, H2 2014 15
Number of Products by Stage and Top 10 Molecule Type, H2 2014 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.